Sessions during the upcoming 15th International Thyroid Congress and annual meeting of the American Thyroid Association will be hitting several hot topics in the treatment of thyroid cancer, including refinement of radioactive iodine treatment, genomic analyses, and targeted treatment. Investigators will be presenting data on the impact of RET and RAS mutation status on overall survival in the EXAM trial, a phase III study of cabozantinib in patients with progressive, metastatic medullary thyroid cancer (Abstract #51).
Investigators will present anticipated results from another phase III study looking at outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib vs. placebo (Abstract #55). A comparison of empiric fixed dosing with a whole body/blood clearance dosimetry-based management approach to radioactive iodine treatment in patients with radioiodine-avid distant metastases from differentiated thyroid cancer is also highly anticipated (Abstract #52) at the 85th Annual Meeting of the AT
SciePro / Science Source
Of note, several sessions (abstract 89), including an plenary presentation by Dr. Shigenobu Nagataki on “Radiation and the Thyroid: From Nagasaki/Hiroshima, Chernobyl to Fukushima.” Dr. Nagataki, who is professor emeritus at Nagasaki (Japan) University School of Medicine, will focus on lessons learned about mass exposure to radiation from these catastrophes. The meeting is being held jointly in Lake Buena Vista, Fla., with the 15th International Thyroid Congress, Oct. 18-23.
Beyond thyroid cancer, investigators will present an analysis of the TACT (Taxotere as Adjuvant Chemotherapy) trial, looking at thyroid autoimmunity as a biomarker of outcome in women with breast cancer (Abstract #23) and a look at second primary malignancies among patients with post-Chernobyl papillary thyroid carcinoma (Abstract #53).
A full look at the program can be found here.
lnikolaides@frontlinemedcom.com
On Twitter @NikolaidesLaura